http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021152370-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca7c109e96ea002b896c90befc5cf334 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78d313d6745df770d11a432f21efec5e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-347 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-79 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0135490a5632c30f1c56b7a0dbcc3c08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a59abd2ef504a3afa049ee72b51ff3b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25655d59f4cd38013cad2f8bb6a834e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f149e6e629af16768895edefb6ef47b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ead40d58f91d19a4d7547463b1d8c6c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9266021a56239906e787ceb83f9b091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_405f3b0188afa493f5e113cdb4b9797f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42ae5a8dc9f83b5b1d13992c2b1ebed7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1907dd73e73f6309bb68356f3220e9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b3bad430e793775cdbedf0b489850b1 |
| publicationDate | 2021-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021152370-A1 |
| titleOfInvention | Method of screening for a chronic kidney disease or glomerulopathy, method of monitoring a response to treatment of a chronic kidney disease or glomerulopathy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy |
| abstract | The object of the present invention is a method of diagnosis of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1 -antitrypsin (serpinal ), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the results of the assay of step (a), wherein this involves estimating a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the level of each of the marker levels determined in (a) ), the probability being estimated based on the levels of each of the markers as determined in subjects known to suffer from a glomerulopathy or a chronic kidney disease; and determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of a glomerulopathy or a chronic kidney disease or not having nor being at a risk thereof as a product of the corresponding probabilities obtained from each marker. A further object of the present invention is a method of monitoring a response to treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: a) measurement of the level, at a first point in time, for three or four or five of the markers selected from a group consisting of serum albumin (ALB), alpha- 1 -antitrypsin (serpinal), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from a subject; b) repeating the assay of step (a) at a later point in time after a period wherein the subject was undergoing a treatment; c) assessing a response to said treatment by comparing the results of the assays of steps (a) and (b), wherein lower marker levels after treatment are indicative of a positive response to treatment. A further object of the present invention is a method of treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1 -antitrypsin (serpinal ), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a); (c) administering treatment against a chronic kidney disease (CKD) or glomerulopathy in the subject evaluated in step (b) as having or being at a risk of chronic kidney disease or glomerulopathy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2768464-C1 |
| priorityDate | 2020-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.